Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally manufacture and supply its leading anticoagulant, Clexane (enoxaparin). The technology transfer agreement is aimed at enabling the French pharmaceutical giant to navigate “changing market dynamics,” as stated in a press release. Production of the medication will take place at Minapharm’s advanced biopharmaceutical facility, which specializes in complex bioengineered proteins. Minapharm brings over two decades of expertise in cellular and bioprocess engineering to the partnership.
According to Sanofi’s financial report for the third quarter of 2023, Clexane is the company’s top-selling core asset, achieving near-blockbuster status with global sales amounting to EUR 862 million (USD 928 million) between January and September of this year.- Flcube.com
